norbertriedel.png

Norbert G. Riedel, PhD

Norton Riedel serves as an advisory board member for Cell Therapy Foundation. Norton is corporate vice president and chief scientific officer for Baxter and has served in that capacity since March 2001.

Norton joined Baxter in 1998 as president of the recombinant unit within Baxter's BioScience business. Prior to joining Baxter, he was head of worldwide biotechnology and worldwide core research functions at Hoechst Marion Roussel, now Sanofi-Aventis.

Norton holds a doctorate of philosophy in biochemistry from the University of Frankfurt. He was a postdoctoral fellow at Harvard University from 1984 to 1987, assistant professor and associate professor of medicine and biochemistry at Boston University School of Medicine from 1987 to 1991, and a visiting professor at Massachusetts Institute of Technology in 1992. He remains affiliated with Boston University as an adjunct professor and also serves as an adjunct professor of medicine for Northwestern University's Feinberg School of Medicine.

Norton serves on the board of directors of Oscient Pharmaceuticals Corporation and Medigene AG. He is chairman of the Illinois Biotechnology Industry Organization and a member of the Advisory Board of Northwestern University's Kellogg School of Management Center for Biotechnology.

 
Get Involved

Don’t let adult stem cell research become idle and delay the potential to improve lives around the world. To support our mission please DONATE HERE.

Newsletter Sign Up
Contact Form
Research Network

The Web-based Adult Stem Cell Research (ASCR) Network exists to encourage and support global collaboration among adult stem cell scientists and match patients with clinical trials. Worldwide membership includes laboratories in Brazil, France, The Netherlands, Singapore, South Korea, Sweden, Taiwan, and USA.

Visit www.ascrnetwork.org

Success Stories

“I hope that someday when I see an older person having trouble with their leg(s), faced with the same problem I had, they have this revolutionary therapy available for them because of the chance I took as a clinical trial patient.”
Jacque Pentell